FIGURE 1 from Urolithin-A Promotes CD8⁺ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation

UroA supplementation slows tumor progression in immunocompetent mice. A, Analysis of tumor growth rate of B16 tumors cells injected in immunocompetent C57/Bl6 mice fed for 4 weeks with UroA-enriched food before tumor cells injection. B, Analysis of tumor growth rate of B16 tumors cells injected in immunodeficient NSG mice fed with control or UroA-enriched diet for 4 weeks before tumor cells injection. C, Analysis of tumor growth rate of B16 tumors implanted in mice as in A and treated with or without anti-CD8 antibody. D, Schematic representation of in vivo feeding experiment followed by withdrawal condition. Mice were fed for 4 weeks with UroA-enriched or control food. Half of the mice were kept under the initial feeding condition, the other half received conventional food. One week after, B16 cells were subcutaneously injected. E, Analysis of tumor growth rate in H. F, Tumor growth rate of B16 tumors in mice as in A and treated with anti PD-1 therapy. Data are mean ± SEM. Each dot represents a biological replicate. In A, control = 6 mice, UroA = 7 mice. In B, control = 5 mice, UroA = 5 mice. In C, control = 6 mice, UroA = 7mice, control+CD8 = 6 mice, UroA+CD8 = 6 mice. In E, control and UroA = 7 mice, on/off condition = 5 mice. In F, each group has 6 mice. Data were analyzed by two-sided Student t test or by ANOVA test followed by multiple comparison test (**, P < 0.01). Representative results of two independent experiments.